Facioscapulohumeral muscular dystrophy (FSHD) is a progressive hereditary neuromuscular disorder, transmitted in an autosomal dominant fashion. Its clinical expression is highly variable, ranging from almost asymptomatic subjects to wheelchair dependent patients. The molecular defect has been linked to chromosome 4q35 markers and has been related to deletions of tandemly repeated sequences located in the subtelomeric region detected by probe pl3E-11 (D4F104S1).
Facioscapulohumeral muscular dystrophy (FSHD) is a neuromuscular disorder characterised by progressive weakness and atrophy of the facial and shoulder girdle muscles, with subsequent involvement of the abdominal, foot extensor, upper arm, and pelvic girdle muscles.' 2 The incidence of the disease, which is transmitted in an autosomal dominant fashion, is estimated as 1 in 20 000. Its penetrance is considered almost complete and in 95% of patients onset is by the age of 20 years. Its clinical expression is highly variable even within the same family, ranging from nearly asymptomatic to wheelchair dependent patients. 3 Pathological alterations in muscle biopsies are consistent with a primary defect of muscle monozygosity (fig 4) was confirmed, compared to a probability of chance association of <<5 x 10'-. Paternity was confirmed with traditional and molecular markers (probability of paternity W=99.999% according to Essen-Moller26) . The muscle biopsy of the asymptomatic twin showed no significant features. There was no abnormality in fibre size, no increase in connective tissue, and no structural changes. Immunocytochemistry also showed no abnormalities and the expression of all proteins studied was normal. Fetal myosin, usually associated with regenerating fibres and thus an indicator of previous muscle damage, was not detected in any fibres. Expression of HLA class I antigens was also normal and confined to the vascular components ( fig 5A, C, E) .
The biopsy of CE, in contrast, showed variation in fibre size with several very small fibres. Occasional necrotic fibres, a little connective tissue, and a few infiltrating cells were also seen. Immunocytochemical labelling for spectrin, dystrophin, the dystrophin associated glycoproteins, and laminin chains was normal. Slight traces of utrophin and HLA class I antigens were detected in some mature fibres. Several of the small fibres also showed HLA expression but these also expressed fetal myosin and were probably immature. Fetal myosin expression was mainly confined to the small fibres ( fig 5B, D, F Haplotype analysis of the family showed that the de novo rearrangement in the D4F104S1 locus had occurred in paternal gametogenesis or postzygotically in the paternal chromosome 4 before the twinning and that the mutated fragment was subsequently transmitted to one of the grandchildren (III.3, fig 1) . The genetic identity of the two twins does not match their clinical picture, with twin CB being almost asymptomatic and CE severely impaired.
To our knowledge, three sets of monozygotic twins affected by FSHD to a different extent have been reported. In one pair, molecular analysis of the D4F104S1 locus showed the presence of a de novo short p1 3E-11 EcoRI fragment only in the affected twin, presumably owing to a postzygotic mutation and thus explaining the phenotypic differences between the two brothers. '9 20 The two other pairs were monozygotic female twins with different clinical expression and carrying a similar EcoRI fragment at the D4F104S1 locus. Other chromosome 4q35 specific markers were not tested. No specific anamnestic records were reported. On account of the gender of the patients, the authors considered that X inactivation might potentially influence the expression of the disease in these subjects.2' This hypothesis does not apply to our cases as the monozygotic twins described here are male. They carry the same mutated fragment but show a different phenotype.
Clinically discordant monozygotic twins for various diseases have often been reported. Discordance is particularly evident, for example, in Wiedeman-Beckwith syndrome (WBS); out of the eight cases of monozygotic twins described,27..9 seven were discordant for the expression of this syndrome, showing one twin with many classical manifestations of the disease and the other having few or none. Minor anomalies observed in most of the normal co-twins were ascribed to the presence of mild forms of WBS and have been explained as a consequence of either environmental factors27 or somatic mosaicism.28 In our case a postzygotic mutation, occurring before the twinning and leading to a different extent of mosaicism in the two brothers, might account for the differences in the clinical manifestation of the muscular dystrophy. However, qualitative evidence of mosaicism, as shown by the presence of an additional less intense band, was not detected by probe p1 3E-1 1 .3"32 Considerable phenotypic variability is described among FSHD patients with wide variation in the age of onset and in the rate of progression as well as in the extent of specific muscle involvement. In an attempt to explain these clinical differences, Lunt et al3 studied a large group of familial cases and found a correlation between the p1 3E-1 1 EcoRI fragment size and age at onset or progression of muscle impairment. The smallest fragments were associated with the earliest age of onset and with earlier use of a wheelchair. The authors proposed that D4F104S1 fragment size determines a part of the variance in age of onset and eventual severity of FSHD. Furthermore, the analysis of the age at onset of clinical signs in patients from multigenerational families suggested that anticipation could occur in FSHD.34 In standardised genotype-phenotype studies it has been shown that the degree of clinical severity present in the parent is significantly lower when compared to the offspring, supporting the hypothesis of anticipation in FSHD." Nevertheless, we have studied families in which almost asymptomatic subjects and wheelchair dependent patients were present within the same generation, with affected members carrying the identical EcoRI fragment (unpublished observations 
